Table 4 Studies about the association of polymorphisms in NRF2 gene with the risk of various cancer

Breast cancer

Hong et al.,2007 [32]

American (505)

rs1806649

CT vs. CC: OR = 1.31; 95%CI = 0.99–1.74; P = 0.20

TT vs. CC: OR = 1.08; 95%CI = 0.66–1.77; p = 0.20

Breast cancer

Hartikainen et al., 2012 [34]

Filander (452)

rs6721961

TT vs. TG/GG: OR = 4.656; 95%CI = 1.350–16.063; P = 0.008

rs6706649

GG vs. TT/TG: OR = 0.215; 95%CI = 0.062–0.741; P = 0.008

rs2706110

AA vs. AG/GG: OR = 0.481; 95%CI = 0.272–0.851; P = 0.011

rs13035806

GG vs. AG/AA: OR = 0.353, 95%CI = 0.115–1.085; P = 0.058

Lung adenocarcinoma

Okano et al., 2013 [35]

Japanese (387)

rs6721961

Gender analysis in AA genotype: OR = 3.48, 95%CI = 1.05–11.51, P = 0.041

Cholangiocarcinoma

Khunluck et al., 2014 [36]

Thailand (198)

rs6726395

GG vs. AA/AG: OR = 1.05; 95%CI = 0.64–1.71; P = 0.852

rs2886161

TT vs. CC/CT: OR = 1.07;95%CI = 0.54–2.09; P = 0.852

rs1806649

CT/TT vs.CC: OR = 1.23;95%CI = 0.61–2.48; P = 0.561

rs10183914

CT/TT vs.CC: OR = 1.08; 95%CI = 0.58–2.02; P = 0.811

Bladder cancer

Reszka et al., 2014 [18]

Polish (244)

rs6721961

CA vs. CC: OR = 0.97; 95%CI = 0.64–1.49; P = 0.91

AA vs. CC: OR = 0.49; 95%CI = 0.12–1.94; P = 0.31

Pancreatic cancer

Yang et al., 2019 [14]

European (8474)

164 NRF2-related genes

No variants in the NRF2 gene to be associated with pancreatic cancer risk

Prostate cancer

Zhang et al., 2019 [33]

American (231)

rs10506328

Dominant model: OR = 1.1; 95%CI = 0.58–2.19; P = 0.777

Recessive model: OR = 1.07; 95%CI = 0.72–1.59; P = 0.748

Additive model: OR = 1.06; 95%CI = 0.78–1.44; P = 0.708

Clear cell renal cell carcinoma

Mihailovic et al., 2021 [12]

Serbian (223)

rs6721961

CA + AA vs. CC: OR = 0.692; 95%CI = 0.370–1.295, P = 0.250

NRF2 (CA + AA) + GSTP1 (Ile/Val + Val/Val) vs. GSTP1 (Ile/Ile) + NRF2 (CC): OR = 2.731; 95%CI = 1.107–6.739

Testicular germ cell tumor

Bumbasirevic et al., 2022 [37]

Serbian (88)

rs6721961

CC + CA vs. AA: OR = 1.42; 95%CI = 0.20–9.72; P = 0.719

Prostate cancer

Djokic et al., 2022 [17]

Serbia (235)

rs6721961

CC vs. CA + AA: OR = 1.28; 95%CI = 0.75–2.17; P = 0.362

SOD2 (CC + CT) + NRF2 (CC) vs. SOD2 (TT) + NRF2 (CA + AA): OR = 4.07; 95%CI = 1.09–3.03; P = 0.006